A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)

BACKGROUND: Metastasis directed therapy (MDT) for patients with oligometastatic disease is associated with improvements in progression free survival (PFS) and overall survival (OS) compared to systemic therapy alone. Additionally, within a prostate-cancer-specific cohort, MDT is able to forestall in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasan, Hamza, Deek, Matthew P., Phillips, Ryan, Hobbs, Robert F., Malek, Reem, Radwan, Noura, Kiess, Ana P., Dipasquale, Shirl, Huang, James, Caldwell, Terry, Leitzel, Jessica, Wendler, Danielle, Wang, Hao, Thompson, Elizabeth, Powell, Jonathan, Dudley, Sara, Deville, Curtiland, Greco, Stephen C., Song, Daniel Y., DeWeese, Theodore L., Gorin, Michael A., Rowe, Steven P., Denmeade, Sam, Markowski, Mark, Antonarakis, Emmanuel S., Carducci, Michael A., Eisenberger, Mario A., Pomper, Martin G., Pienta, Kenneth J., Paller, Channing J., Tran, Phuoc T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268477/
https://www.ncbi.nlm.nih.gov/pubmed/32487038
http://dx.doi.org/10.1186/s12885-020-07000-2

Ejemplares similares

Ejemplares similares